EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro interactions of proton pump inhibitors and azoles against pathogenic fungi

Lujuan Gao, Xuqiong Xia, Xiao Gong, Heng Zhang, Yi Sun

Frontiers in Cellular and Infection Microbiology · 17.01.2024 · 14

DOI: 10.3389/fcimb.2024.1296151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 17.01.2024. Verfasst von Lujuan Gao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China. Hauptthemen laut MEDLINE: Azoles, Proton Pump Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province, Xiamen Municipal Bureau of Science and Technology, Hebei Provincial Key Research Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Azole resistance has been increasingly reported and become an issue for clinical managements of invasive mycoses. New strategy with combination therapy arises as a valuable and promising alternative option. The aim of the present study is to investigate the in vitro combinational effect of proton pump inhibitors (PPIs) and azoles against pathogenic fungi.

Methods

In vitro interactions of PPIs including omeprazole (OME), lansoprazole (LAN), pantoprazole (PAN), and rabeprazole (RAB), and commonly used azoles including itraconazole (ITC), posaconazole (POS), voriconazole (VRC) and fluconazole (FLC), were investigated via broth microdilution chequerboard procedure adapted from the CLSI M27-A3 and M38-A2. A total of 67 clinically isolated strains, namely 27 strains of Aspergillus spp., 16 strains of Candida spp., and 24 strains of dematiaceous fungi, were studied. C. parapsilosis (ATCC 22019) and A. flavus (ATCC 204304) was included to ensure quality control.

Results

PPIs individually did not exert any significant antifungal activity. The combination of OME with ITC, POS, or VRC showed synergism against 77.6%, 86.6%, and 4% strains of tested pathogenic fungi, respectively, while synergism of OME/FLC was observed in 50% strains of Candida spp. Synergism between PAN and ITC, POS, or VRC was observed against 47.8%, 77.6% and 1.5% strains of tested fungi, respectively, while synergism of PNA/FLC was observed in 50% strains of Candida spp. Synergism of LAN with ITC, POS, or VRC was observed against 86.6%, 86.6%, and 3% of tested strains, respectively, while synergism of LAN/FLC was observed in 31.3% strains of Candida spp. Synergy of the combination of RAB with ITC, POS, or VRC was observed against 25.4%, 64.2%, and 4.5% of tested strains, respectively, while synergism of RAB/FLC was observed in 12.5% of Candida spp.. Among PPIs, synergism was least observed between RAB and triazoles, while among triazoles, synergism was least observed between VRC and PPIs. Among species, synergy was much more frequently observed in Aspergillus spp. and dematiaceous fungi as compared to Candida spp. Antagonism between PPIs with ITC or VRC was occasionally observed in Aspergillus spp. and dematiaceous fungi. It is notable that PPIs combined with azoles showed synergy against azole resistant A. fumigatus , and resulted in category change of susceptibility of ITC and POS against Candida spp.

Discussion

The results suggested that PPIs combined with azoles has the potential to enhance the susceptibilities of azoles against multiple pathogenic fungi and could be a promising strategy to overcome azole resistance issues. However, further investigations are warranted to study the combinational efficacy in more isolates and more species, to investigate the underlying mechanism of interaction and to evaluate the potential for concomitant use of these agents in human.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzolesProton Pump InhibitorsHumansFungiAntifungal AgentsTriazolesVoriconazoleFluconazoleCandidaAspergillusCandida parapsilosisMicrobial Sensitivity TestsDrug Resistance, Fungal

Stichwörter der Autor:innen

AspergillusCandidaazoledematiaceous fungifungiomeprazolepantoprazoleproton pump inhibitors

Substanzen

AzolesProton Pump InhibitorsAntifungal AgentsTriazolesVoriconazoleFluconazole

Autor:innen und Institutionen

  • Department of Dermatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China.
  • Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Dermatology, Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Dermatology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.

Förderung

  • Natural Science Foundation of Fujian Province
  • Xiamen Municipal Bureau of Science and Technology
  • Hebei Provincial Key Research Projects

Zitieren

APA

Gao, L., Xia, X., Gong, X., Zhang, H., & Sun, Y. (2024). In vitro interactions of proton pump inhibitors and azoles against pathogenic fungi. Frontiers in Cellular and Infection Microbiology, 14. https://doi.org/10.3389/fcimb.2024.1296151

Vancouver

Gao L, Xia X, Gong X, Zhang H, Sun Y. In vitro interactions of proton pump inhibitors and azoles against pathogenic fungi. Frontiers in Cellular and Infection Microbiology. 2024;14. doi:10.3389/fcimb.2024.1296151

BibTeX
@article{Gao2024,
  author = {Gao, Lujuan and Xia, Xuqiong and Gong, Xiao and Zhang, Heng and Sun, Yi},
  title = {In vitro interactions of proton pump inhibitors and azoles against pathogenic fungi},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fcimb.2024.1296151}
}
Kostenlos starten →